TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that its executive management team will participate in the ATB Capital Markets 2024 Life Sciences Institutional Investor Conference being held on September 18, 2024 in New York City.
Jason Wild, Executive Chairman, will participate in a panel discussion, “Regulatory Ripples, Market Impacts: How Cannabis Reform Will Impact Valuations and Investor Engagement”, alongside Dan Ahrens, Chief Operating Officer of Advisor Shares and moderated by Frederico Gomes, Director of Institutional Research in Life Sciences at ATB Capital markets, on Wednesday, September 18th at 8:00 AM ET.
Management including Mr. Wild, Ziad Ghanem, Chief Executive Officer, and Keith Stauffer, Chief Financial Officer, will host one-on-one meetings throughout the conference. Please reach out to your conference representative or email IR@TerrAscend.com.
About TerrAscend
TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including vertically integrated operations in Pennsylvania, New Jersey, Maryland, Michigan and California through TerrAscend Growth Corp. and retail operations in Canada through TerrAscend Canada Inc. (“TerrAscend”). TerrAscend operates The Apothecarium, Gage and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.
For more information regarding TerrAscend:
Keith Stauffer
Chief Financial Officer
IR@terrascend.com
855-837-7295
Briana Chester
MATTIO Communications
424-465-4419
terrascend@mattio.com
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients…
TAMPA, Fla.--(BUSINESS WIRE)--#cryotherapy--Next Health, the world's most advanced brand of proactive healthcare centers, is bringing…
TORONTO, ON / ACCESSWIRE / September 27, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma…
Visit Covalon at booth 523 to discover the latest in compassionate vascular access solutions MISSISSAUGA,…
WASHINGTON & OXFORD, England--(BUSINESS WIRE)--#Healthcare--Perspectum announced two research studies that were recently published, bringing hope…
SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading…